Veracyte, Inc. (VCYT)

Market Cap	2.35B
Revenue (ttm)	445.76M
Net Income (ttm)	24.14M
Shares Out	77.94M
EPS (ttm)	0.31
PE Ratio	97.16
Forward PE	25.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	710,014
Open	30.77
Previous Close	31.10
Day's Range	29.69 - 31.04
52-Week Range	18.61 - 47.32
Beta	1.80
Analysts	Buy
Price Target	42.67 (+41.67%)
Earnings Date	May 6, 2025

About VCYT

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 30, 2013
• Employees: 824
• Stock Exchange: NASDAQ
• Ticker Symbol: VCYT
• Website: https://www.veracyte.com

Analyst Forecast

According to 9 analysts, the average rating for VCYT stock is "Buy." The 12-month stock price forecast is $42.67, which is an increase of 41.67% from the latest price.

Price Target

$42.67

(41.67% upside)

Analyst Consensus: Buy